Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma

References

• Romeo S, Bovee JVMG, Jundt G. Undifferentiated high grade pleomorphic sarcoma. In Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. (eds). WHO Classification of Tumours of Soft Tissue and Bone. Fourth Edition. Lyon: IARC Press; 364-365.
   Google Scholar
• Fletcher CD. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology. 2006;48(1):3-12. doi:10.1111/j.1365-2559.2005.02284.x
   PubMed Web of Science ®Google Scholar
• Brennan MF, Antonescu CR, Moraco N, Singer S. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Annals Surg. 2014;260(3):416-21; discussion 21–2. doi:10.1097/SLA.0000000000000869
   PubMed Web of Science ®Google Scholar
• Gladdy RA, Qin LX, Moraco N, Edgar MA, Antonescu CR, Alektiar KM, Brennan MF, Singer S. Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas? J Clin Oncol. 2010;28(12):2064-9. doi:10.1200/JCO.2009.25.1728
   PubMed Web of Science ®Google Scholar
• Riad S, Biau D, Holt GE, Werier J, Turcotte RE, Ferguson PC, Griffin AM, Dickie CI, Chung PW, Catton C, et al. The clinical and functional outcome for patients with radiation-induced soft tissue sarcoma. Cancer. 2012;118(10):2682-92. doi:10.1002/cncr.26543
   PubMed Web of Science ®Google Scholar
• Goldblum JR. An approach to pleomorphic sarcomas: can we subclassify, and does it matter? Mod Pathol. 2014;27(Suppl 1):S39-46. doi:10.1038/modpathol.2013.174
   PubMed Web of Science ®Google Scholar
• Fletcher CDM, Unni KK, Mertens F. Pathology and Genetics of Soft Tissue and Bone: World Health Organization Classification of Tumors. Fletcher CDM, editor. Lyon, France: IARC Press; 2002.
   Google Scholar
• Donato Di Paola E, Nielsen OS, Tissue ES, Bone Sarcoma G. The EORTC soft tissue and bone sarcoma group. Eur Organisation for Res Treatment Cancer. 2002;38 Suppl 4:S138-41.
   Google Scholar
• Nascimento AF, Raut CP. Diagnosis and management of pleomorphic sarcomas (so-called “MFH”) in adults. J Surg Oncol. 2008;97(4):330-9. doi:10.1002/jso.20972
   PubMed Web of Science ®Google Scholar
• Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007;25(19):2755-63. doi:10.1200/JCO.2006.10.4117
   PubMed Web of Science ®Google Scholar
• Wardelmann E, Schildhaus HU, Merkelbach-Bruse S, Hartmann W, Reichardt P, Hohenberger P, Büttner R. Soft tissue sarcoma: from molecular diagnosis to selection of treatment. Pathological diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies. Annals Oncol. 2010;21 Suppl 7:vii265-9. doi:10.1093/annonc/mdq381
   PubMed Web of Science ®Google Scholar
• Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10(3):143-53. doi:10.1038/nrclinonc.2013.10
   PubMed Web of Science ®Google Scholar
• Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, Parsons JT, Horwitz AR. Cell migration: integrating signals from front to back. Science 2003;302(5651):1704-9. doi:10.1126/science.1092053
   PubMed Web of Science ®Google Scholar
• Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 2014;15(1):7-24. doi:10.1038/nrc3860
   Web of Science ®Google Scholar
• Garcia-Echeverria C. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorganic Med Chem Lett. 2010;20(15):4308-12. doi:10.1016/j.bmcl.2010.05.099
   PubMed Web of Science ®Google Scholar
• O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66(3):1500-8. doi:10.1158/0008-5472.CAN-05-2925
   PubMed Web of Science ®Google Scholar
• Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 2011;30(22):2547-57. doi:10.1038/onc.2010.626
   PubMed Web of Science ®Google Scholar
• Muellner MK, Uras IZ, Gapp BV, Kerzendorfer C, Smida M, Lechtermann H, Craig-Mueller N, Colinge J, Duernberger G, Nijman SM. A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat Chem Biol. 2011;7(11):787-93. doi:10.1038/nchembio.695
   PubMed Web of Science ®Google Scholar
• Britschgi A, Andraos R, Brinkhaus H, Klebba I, Romanet V, Muller U, Murakami M, Radimerski T, Bentires-Alj M. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell. 2012;22(6):796-811. doi:10.1016/j.ccr.2012.10.023
   PubMed Web of Science ®Google Scholar
• Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell. 2011;19(1):58-71. doi:10.1016/j.ccr.2010.10.031
   PubMed Web of Science ®Google Scholar
• Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, Gao S, Mills GB, Brugge JS. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell. 2012;21(2):227-39. doi:10.1016/j.ccr.2011.12.024
   PubMed Web of Science ®Google Scholar
• Tomita Y, Morooka T, Hoshida Y, Zhang B, Qiu Y, Nakamichi I, Hamada K, Ueda T, Naka N, Kudawara I, et al. Prognostic significance of activated AKT expression in soft-tissue sarcoma. Clin Cancer Res. 2006;12(10):3070-7. doi:10.1158/1078-0432.CCR-05-1732
   PubMed Web of Science ®Google Scholar
• Valkov A, Kilvaer TK, Sorbye SW, Donnem T, Smeland E, Bremnes RM, Busund LT. The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas. J Translational Med. 2011;9:200. doi:10.1186/1479-5876-9-200
   PubMed Web of Science ®Google Scholar
• Dobashi Y, Suzuki S, Sato E, Hamada Y, Yanagawa T, Ooi A. EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors. Mod Pathol. 2009;22(10):1328-40. doi:10.1038/modpathol.2009.104
   PubMed Web of Science ®Google Scholar
• Lahat G, Zhang P, Zhu QS, Torres K, Ghadimi M, Smith KD, Wang WL, Lazar AJ, Lev D. The expression of c-Met pathway components in unclassified pleomorphic sarcoma/malignant fibrous histiocytoma (UPS/MFH): a tissue microarray study. Histopathology. 2011;59(3):556-61. doi:10.1111/j.1365-2559.2011.03946.x
   PubMed Web of Science ®Google Scholar
• Matushansky I, Hernando E, Socci ND, Mills JE, Matos TA, Edgar MA, Singer S, Maki RG, Cordon-Cardo C. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest. 2007;117(11):3248-57. doi:10.1172/JCI31377
   PubMed Web of Science ®Google Scholar
• Butler DE, Marlein C, Walker HF, Frame FM, Mann VM, Simms MS, et al. Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer. Oncotarget. 2017;8(34):56698-56713. doi:10.18632/oncotarget.18082
   PubMed Web of Science ®Google Scholar
• Ning C, Liang M, Liu S, Wang G, Edwards H, Xia Y, Polin L, Dyson G, Taub JW, Mohammad RM, et al. Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. Oncotarget. 2017;8(27):44295-44311. doi:10.18632/oncotarget.17869
   PubMed Web of Science ®Google Scholar
• Rewcastle GW, Kolekar S, Buchanan CM, Gamage SA, Giddens AC, Tsang KY, Kendall JD, Singh R, Lee WJ, Smith GC, et al. Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kalpha, in comparison to established pan PI3K inhibitors. Oncotarget. 2017;8(29):47725-47740. doi:10.18632/oncotarget.17730
   PubMed Web of Science ®Google Scholar
• Riedl A, Schlederer M, Pudelko K, Stadler M, Walter S, Unterleuthner D, Unger C, Kramer N, Hengstschläger M, Kenner L, et al. Comparison of cancer cells in 2D vs 3D culture reveals differences in AKT-mTOR-S6K signaling and drug responses. J Cell Sci. 2017;130(1):203-18. doi:10.1242/jcs.188102
   PubMed Web of Science ®Google Scholar
• Kim EK, Yun SJ, Ha JM, Kim YW, Jin IH, Yun J, Shin HK, Song SH, Kim JH, Lee JS, et al. Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis. Oncogene. 2011;30(26):2954-63. doi:10.1038/onc.2011.22
   PubMed Web of Science ®Google Scholar
• Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, Gao J, Brueggen J, Capraro HG, Cozens R, et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell. 2004;5(3):231-9.
   PubMed Web of Science ®Google Scholar
• Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12(3):159-69. doi:10.1038/nrc3215
   PubMed Web of Science ®Google Scholar
• Sachdev D, Zhang X, Matise I, Gaillard-Kelly M, Yee D. The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene. 2010;29(2):251-62. doi:10.1038/onc.2009.316
   PubMed Web of Science ®Google Scholar
• Ning J, Wakimoto H, Peters C, Martuza RL, Rabkin SD. Rad51 degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma. J Natl Cancer Inst. 2017;109(3):1-13. doi:10.1093/jnci/djw229
   PubMedGoogle Scholar
• Chaib I, Karachaliou N, Pilotto S, Codony Servat J, Cai X, Li X, Drozdowskyj A, Servat CC, Yang J, Hu C, et al. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) pathway in EGFR-Mutant NSCLC. J Natl Cancer Inst. 2017;109(9):1-12. doi:10.1093/jnci/djx014
   Google Scholar
• Xie J, Liu JH, Liu H, Liao XZ, Chen Y, Lin MG, Gu YY, Liu TL, Wang DM, Ge H, et al. Tanshinone IIA combined with adriamycin inhibited malignant biological behaviors of NSCLC A549 cell line in a synergistic way. BMC Cancer. 2016;16(1):899. doi:10.1186/s12885-016-2921-x
   PubMed Web of Science ®Google Scholar
• Chou T-C, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enz. Regul. 1984;22:27-55.
   Google Scholar
• Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM. p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev. 2004;18(8):862-76. doi:10.1101/gad.1185504
   PubMed Web of Science ®Google Scholar
• Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med. 2002;8(10):1153-60. doi:10.1038/nm761
   PubMed Web of Science ®Google Scholar
• Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med. 2002;8(10):1145-52. doi:10.1038/nm759
   PubMed Web of Science ®Google Scholar
• Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P, Bellacosa A, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med. 2002;8(10):1136-44. doi:10.1038/nm762
   PubMed Web of Science ®Google Scholar
• Baumann P, Schneider L, Mandl-Weber S, Oduncu F, Schmidmaier R. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anti-Cancer Drugs. 2012;23(1):131-8. doi:10.1097/CAD.0b013e32834c8683
   PubMed Web of Science ®Google Scholar
• Chang KY, Tsai SY, Wu CM, Yen CJ, Chuang BF, Chang JY. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin Cancer Res. 2011;17(22):7116-26. doi:10.1158/1078-0432.CCR-11-0796
   PubMed Web of Science ®Google Scholar
• Fokas E, Yoshimura M, Prevo R, Higgins G, Hackl W, Maira SM, Bernhard EJ, McKenna WG, Muschel RJ. NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity. Radiat Oncol. 2012;7:48. doi:10.1186/1748-717X-7-48
   PubMed Web of Science ®Google Scholar
• Glienke W, Maute L, Wicht J, Bergmann L. The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines. Tumour Biol. 2012;33(3):757-65. doi:10.1007/s13277-011-0290-2
   PubMed Web of Science ®Google Scholar
• Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Rasp KH, Illing B, Dohner H, Döhner K, Schittenhelm MM. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. Mol Cancer. 2013;12:46. doi:10.1186/1476-4598-12-46
   PubMed Web of Science ®Google Scholar
• Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, Lin L, Ellis MJ. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res. 2011;13(2):R21. doi:10.1186/bcr2833
   PubMed Web of Science ®Google Scholar
• Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, Milikowski C, Bishopric NH, Minn AJ, Creighton CJ, et al. PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Res Treatment. 2013;138(2):369-81. doi:10.1007/s10549-012-2389-6
   PubMed Web of Science ®Google Scholar
• Larrea MD, Hong F, Wander SA, da Silva TG, Helfman D, Lannigan D, Smith JA, Slingerland JM. RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility. Proc Natl Acad Sci U S A. 2009;106(23):9268-73. doi:10.1073/pnas.0805057106
   PubMed Web of Science ®Google Scholar
• Lee GE, Yu EY, Cho CH, Lee J, Muller MT, Chung IK. DNA-protein kinase catalytic subunit-interacting protein KIP binds telomerase by interacting with human telomerase reverse transcriptase. J Biol Chem. 2004;279(33):34750-5. doi:10.1074/jbc.M401843200
   PubMed Web of Science ®Google Scholar
• Denicourt C, Dowdy SF. Cip/Kip proteins: more than just CDKs inhibitors. Genes Dev. 2004;18(8):851-5. doi:10.1101/gad.1205304
   PubMed Web of Science ®Google Scholar
• Lee S, Helfman DM. Cytoplasmic p21Cip1 is involved in Ras-induced inhibition of the ROCK/LIMK/cofilin pathway. J Biol Chem. 2004;279(3):1885-91. doi:10.1074/jbc.M306968200
   PubMed Web of Science ®Google Scholar
• Zhou H, Kramer RH. Integrin engagement differentially modulates epithelial cell motility by RhoA/ROCK and PAK1. J Biol Chem. 2005;280(11):10624-35. doi:10.1074/jbc.M411900200
   PubMed Web of Science ®Google Scholar
• King H, Aleksic T, Haluska P, Macaulay VM. Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treatment Rev. 2014;40(9):1096-105. doi:10.1016/j.ctrv.2014.07.004
   PubMed Web of Science ®Google Scholar
• Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst. 2012;104(13):975-81. doi:10.1093/jnci/djs258
   PubMedGoogle Scholar
• Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D'Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. 2012;30(1):78-84. doi:10.1200/JCO.2011.35.6329
   PubMed Web of Science ®Google Scholar
• Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, et al. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013;14(4):371-82. doi:10.1016/S1470-2045(13)70049-4
   PubMed Web of Science ®Google Scholar
• Dineen SP, Roland CL, Feig R, May C, Zhou S, Demicco E, et al. Radiation-associated undifferentiated Pleomorphic Sarcoma is associated with worse clinical outcomes than Sporadic Lesions. Annals Surgical Oncol. 2015;22(12):3913-20. doi:10.1245/s10434-015-4453-z
   Web of Science ®Google Scholar
• Ruping K, Altendorf-Hofmann A, Chen Y, Kampmann E, Gibis S, Lindner L, Katenkamp D, Petersen I, Knösel T. High IGF2 and FGFR3 are associated with tumour progression in undifferentiated pleomorphic sarcomas, but EGFR and FGFR3 mutations are a rare event. J Cancer Res Clin Oncol. 2014;140(8):1315-22. doi:10.1007/s00432-014-1700-9
   PubMed Web of Science ®Google Scholar
• Peng T, Zhang P, Liu J, Nguyen T, Bolshakov S, Belousov R, Young ED, Wang X, Brewer K, López-Terrada DH, et al. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. Lab Invest. 2011;91(3):392-403. doi:10.1038/labinvest.2010.185
   PubMed Web of Science ®Google Scholar
• Katanasaka Y, Kodera Y, Yunokawa M, Kitamura Y, Tamura T, Koizumi F. Synergistic anti-tumor effects of a novel phosphatidyl inositol-3 kinase/mammalian target of rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lung cancer cell lines. Cancer Letters. 2014;347(2):196-203. doi:10.1016/j.canlet.2014.02.025
   PubMed Web of Science ®Google Scholar
• Stauffer F, Cowan-Jacob SW, Scheufler C, Furet P. Identification of a 5-[3-phenyl-(2-cyclic-ether)-methylether]-4-aminopyrrolo[2,3-d]pyrimidine series of IGF-1R inhibitors. Bioorg Med Chem Lett. 2016;26(8):2065-7. doi:10.1016/j.bmcl.2016.02.074
   PubMed Web of Science ®Google Scholar
• Zou CY, Smith KD, Zhu QS, Liu J, McCutcheon IE, Slopis JM, Meric-Bernstam F, Peng Z, Bornmann WG, Mills GB, et al. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther. 2009;8(5):1157-68. doi:10.1158/1535-7163.MCT-08-1008
   PubMed Web of Science ®Google Scholar